Showing 1591-1600 of 2314 results for "".
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meetinghttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from N
- Avellino Donates $25,000 to National Keratoconus Foundation to Support World Keratoconus Day and Disease Educationhttps://modernod.com/news/avellino-donates-25000-to-national-keratoconus-foundation-to-support-world-keratoconus-day-and-disease-education/2480393/Avellino Lab USA, in honor of World Keratoconus Day, announced a $25,000 donation to the National Keratoconus Foundation (NKCF) to support their educational efforts for this sight-threatening disease. Part of the Gavin Herbert Eye Institute at the University of California, Irvine, NKCF
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,
- Oertli Instrumente Acquires Majority Interest in Ophthalmic Instrument Maker Domedics AGhttps://modernod.com/news/oertli-instrumente-acquires-majority-interest-in-ophthalmic-instrument-maker-domedics-ag/2480317/Oertli Instrumente announced it has acquired the majority of shares of Dattwil, Switzerland-based Domedics AG.</
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Nicox Does Not Meet Primary or Secondary Endpoints in Phase 2b Mississippi Blepharitis Trialhttps://modernod.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/Nicox SA announced the results from its Mississippi phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations o
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter
- FDA Advisory Panel Set to Review COVID-19 Booster Doseshttps://modernod.com/news/fda-advisory-panel-set-to-review-covid-19-booster-doses/2479485/The FDA announced that an advisory committee will meet on September 17 to discuss the issue of booster doses of COVID-19 vaccines, according to a FirstWord report. The Vaccines and Related Biological Products Advisory Committee will spec
- Regeneron Announces Topline Phase 2 Data of High-Dose Aflibercept in Wet AMDhttps://modernod.com/news/regeneron-announces-topline-phase-2-data-of-high-dose-aflibercept-in-wet-amd/2479468/Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients